Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-24 Phase 2 Study in Infants
NCT05844423Phase 2Completed
- Sponsor
- Vaxcyte
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 24-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD) and pneumococcal disease (4 arms), sponsored by Vaxcyte. Primary endpoints: Percentage of participants with any solicited local injection site Adverse Events, Percentage of participants with any solicited systemic Adverse Events and 1 more. Started Mar 2023; status: completed.
02
Drugs
24-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)pneumococcal disease
Beyond the preview
Go deeper on NCT05844423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844423.